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Structured abstract 29 
Purpose: To investigate the relationship between vectorcardiography (VCG) and 30 
myocardial scar on cardiac magnetic resonance (CMR) imaging, and whether combining 31 
these metrics may improve cardiac resynchronization therapy (CRT) response 32 
prediction.  33 
Methods: Thirty-three CRT patients were included. QRSarea, Tarea and QRSTarea were 34 
derived from the ECG-synthesized VCG. CMR parameters reflecting focal scar core 35 
(Scar2SD, Gray2SD) and diffuse fibrosis (pre-T1, extracellular volume [ECV]) were 36 
assessed. CRT response was defined as ≥15% reduction in left ventricular end-systolic 37 
volume after six months’ follow-up. 38 
Results: VCG QRSarea, Tarea and QRSTarea inversely correlated with focal scar (R=-0.44–-39 
0.58 for Scar2SD, p≤0.010), but not with diffuse fibrosis. Scar2SD, Gray2SD and QRSarea 40 
predicted CRT response with AUCs of 0.692 (p=0.063), 0.759 (p=0.012) and 0.737 41 
(p=0.022) respectively. A combined ROC-derived threshold for Scar2SD and QRSarea 42 
resulted in 92% CRT response rate for patients with large QRSarea and small Scar2SD or 43 
Gray2SD.  44 
Conclusion: Incremental predictive value for CRT response is achieved by a combined 45 
CMR-QRSarea analysis.  46 
 47 
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Highlights  53 
 The relationship between vectorcardiography (VCG) and myocardial scar 54 
defined by cardiac magnetic resonance imaging (CMR) is elucidated. 55 
 VCG QRSarea significantly inversely correlates with focal scar, suggesting that 56 
myocardial scar leads to a smaller QRSarea. 57 
 By combining QRSarea and CMR focal scar assessment, CRT response prediction 58 
improves beyond that by either VCG or scar parameters alone.  59 
 60 
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Introduction 76 
Cardiac resynchronization therapy (CRT) is an effective treatment for patients with 77 
symptomatic heart failure (HF), reduced systolic left ventricular (LV) function, and wide 78 
QRS complex. Nevertheless, about one-third of patients eligible according to current 79 
guidelines fail to benefit from CRT. Suboptimal CRT response has been attributed to 80 
factors including QRS duration (QRSd) <150 ms, non-left bundle branch block (non-81 
LBBB) morphology, ischemic cardiomyopathy, and suboptimal LV lead position.(1)  82 
Parameters derived from the three-dimensional (3D) vectorcardiogram (VCG) have 83 
recently been shown to be more accurate than QRSd or morphology in predicting CRT 84 
response.(2) The VCG represents the electrical heart vector in three orthogonal 85 
directions (X, Y, and Z) and can be derived from a true VCG lead system or synthesized 86 
from the standard 12-lead ECG using a mathematical transformation matrix.(3) The 3D 87 
area of the VCG QRS- (QRSarea) and T-loop (Tarea) are supposed to reflect unopposed 88 
electrical forces during ventricular depolarization and repolarization respectively. Both 89 
QRSarea and Tarea have been shown to be strong predictors for LV reverse remodeling 90 
after CRT.(2, 4) In a small study it was observed that QRSarea was relatively reduced in 91 
patients with ischemic cardiomyopathy, suggesting an association between QRSarea  and 92 
myocardial scar.(4) 93 
Ischemic cardiomyopathy, the presence and size of scar burden, and positioning the LV 94 
lead in scar are negatively associated with CRT outcome.(5) CMR is able to characterize 95 
different types of myocardial scar including focal scar with delayed enhancement (DE-96 
CMR) and diffuse fibrosis with T1 mapping. Recent work demonstrated that focal scar, 97 
but not diffuse fibrosis, was associated with poor CRT response.(6) 98 
Summarizing the above literature, it appears that certain electrical characteristics from 99 
the VCG and low myocardial scar burden is favorable for response to CRT. The 100 
association between VCG and myocardial scar as measured by CMR is however not 101 
known.  102 
The purpose of this study was therefore to investigate the association between VCG 103 
parameters and myocardial scar (both focal and diffuse) on CMR in HF patients with 104 
ventricular conduction disturbance, and whether combining VCG with CMR scar 105 
parameters improves prediction to CRT response.  106 
 107 
Methods  108 
 6 
Study population  109 
Consecutive patients referred for CRT device implantation who underwent CMR 110 
imaging as part of their clinical workup were prospectively enrolled at Guys and St 111 
Thomas’ NHS Trust hospital as previously described.(6) The South-East London 112 
Research Ethics Committee approved the study protocol and all patients gave written 113 
consent.  114 
 115 
Vectorcardiography analyses  116 
Standard 12-lead ECG’s were recorded prior to CRT implantation in supine position 117 
using the ECG machine MAC 5500 HD (GE Healthcare, Chicago, IL). The digital PDF ECG 118 
files with vector graphics were used to extract the original digital ECG-signal. VCGs were 119 
semi-automatically synthesized from these digital ECG signals using custom software 120 
programmed in MATLAB.(4) The Kors transformation matrix was used to transform the 121 
12-lead ECG to VCG.(3) The onset and end of the QRS-complex and T-wave were 122 
manually set on the three overlaid orthogonal leads (X, Y, and Z) of the VCG by two 123 
electrophysiologists blinded to CRT outcome. QRSarea, Tarea, and QRSTarea were defined as 124 
the 3D areas of respectively the QRS-, T-wave, and QRST loop from the VCG between the 125 
loop and baseline in X, Y, and Z direction calculated as QRSarea = (QRSarea,x2 + QRSarea,y2  + 126 
QRSarea,z2)1/2,  Tarea  = (Tarea,x2 + Tarea,y2 + Tarea,z2)1/2, and QRSTarea = (QRSTarea,x2 + 127 
QRSTarea,y2  + QRSTarea,z2)1/2 .(4)  128 
 129 
Cardiac magnetic resonance imaging  130 
Patients underwent CMR prior to their CRT implantation using a 1.5T scanner with a 131 
32–channel coil (Philips Healthcare, Best) as described previously.(6) Two independent 132 
CMR experts, blinded to CRT outcome, assessed the CMR images. In case of discrepancy, 133 
consensus between the reviewers was reached. LV mass was quantified using CMR42 134 
(Circle Cardiovascular Imaging Inc, Calgary) software and used to index the delayed 135 
enhancement (DE-CMR) quantification of focal scar. The extent of scar core was 136 
automatically quantified using the 2-standard deviation (2SD) method, defined as the 137 
region with signal intensity (SI) >2SD above reference myocardium (Scar2SD). The 138 
extent of Gray zone was quantified by the difference in SI between Scar2SD and Scar3SD 139 
(Gray2SD).  140 
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Conceptually scar core comprises dense and non-viable fibrosis, creating zones of 141 
conduction block. Grayzone comprises an admixture of viable and non-viable myocytes, 142 
creating zones of slow conduction which may alter to electrical and mechanical 143 
remodeling.  Both metrics are clinically relevant in the context of LV function and 144 
mortality. Given that the burden of scar core, i.e. homogeneously non-viable 145 
myocardium, is ubiquitously high amongst advanced heart failure patients, the 146 
assessment of the remaining viable tissue may play an important role in predicting the 147 
capacity of the LV to positively remodel with CRT. Grayzone is an independent predictor 148 
for mortality after myocardial infarction and is associated with ventricular 149 
arrhythmias,(7, 8) while focal scar is associated with clinical outcome and LV reverse 150 
remodeling after cardiac resynchronization therapy (CRT).(9, 10)  151 
All DE-CMR scar parameters were expressed as a percentage of LV mass (%LV). T1 152 
relaxation maps were processed using a customized software plugin with Osirix 153 
(Pixmeo, Geneva), from which the diffuse fibrosis parameters pre-contrast T1 (pre T1) 154 
and extracellular volume index (ECV) was calculated.(6) A graphical representation of 155 
the VCG and CMR assessment is provided in Figure 1. 156 
 157 
Cardiac resynchronization therapy implantation and response determination 158 
The LV lead was preferentially targeted in a posterolateral, lateral or anterolateral 159 
coronary sinus tributary, with pacing sites preferentially chosen in a basal position 160 
remote from CMR scar. Trans-thoracic echocardiography was assessed pre- and six 161 
months post-CRT implantation using a GE Vivid 7 scanner (General Electric-Vingmed, 162 
Milwaukee, Wisconsin). Standard 2D images of LV dimensions and ejection fraction 163 
(LVEF) were acquired in standard apical 2- and 4-chamber views. LV end-diastolic and 164 
end-systolic volumes (LVEDV, LVESV) were used to estimate LVEF using the 2-165 
dimensional modified biplane Simpson’s method (EchoPac 6.0.1, General Electric 166 
Vingmed). CRT response was defined as an echocardiographic LVESV reduction of 167 
≥15% of baseline afters six months’ follow-up.  Echocardiography was performed by 168 
sonographers blinded to both VCG and CMR data. 169 
 170 
Statistical analyses 171 
Statistical analyses were performed using SPSS 24.0 (SPSS Inc., Chicago, Illinois) and 172 
MATLAB (Matlab 2016B, MathWorks, Natick, MA). Continuous variables are expressed 173 
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as mean±SD or median and interquartile range (IQR) and dichotomous variables in 174 
frequencies and percentages. Spearman correlation analyses were carried out between 175 
and within VCG and CMR parameters. Parameter differences between CRT responders 176 
vs. non-responders were compared using Mann Whitney U-tests. Receiver operating 177 
characteristics (ROC) curves were generated to evaluate the diagnostic accuracy of all 178 
parameters in identifying CRT response and to find optimal cut-off values. These cut-off 179 
values were used to dichotomize the population to groups ≤cut-off and >cut-off, and the 180 
number of CRT responders for every subgroup were compared using Chi-squared 181 
analyses. The most promising VCG and CMR scar parameters were combined in a cross-182 
tab to evaluate its joint effect on CRT response prediction. Differences within the 183 
crosstabs were evaluated using Fisher’s exact tests. Significance was defined as p-value 184 
<0.05 using two-tailed analysis.  185 
 186 
Results 187 
Study population 188 
Thirty-three consecutive patients with either non-ischemic (n = 17) or ischemic (n = 16) 189 
cardiomyopathy were included. Patient characteristics are provided in Table 1.  190 
 191 
Cardiac resynchronization therapy response 192 
Nineteen out of 33 patients (58%) showed a reduction in LVESV of ≥15% after six 193 
months follow-up. Mean Scar2SD and Gray2SD tended to be lower in CRT responders than 194 
in non-responders, although this difference was significant for Gray2SD (p<0.011), but it 195 
did not reach a significance level for Scar2SD (p=0.065).  Pre-T1 and ECV however did not 196 
differ between CRT responders and non-responders (p=0.152 and 0.706, respectively). 197 
QRSarea, but not Tarea or QRSTarea, was significantly higher in responders than in non-198 
responders to CRT (p = 0.021; Table 2).  199 
There was a positive correlation between Scar2SD and Gray2SD and ΔLVESV (R: 0.46-0.55, 200 
p≤0.008), while there was no significant correlation between Pre-T1 and ECV and 201 
ΔLVESV. From the VCG parameters, QRSarea and QRSTarea inversely correlated with 202 
ΔLVESV (both R: -0.44, p = 0.010), while there was no correlation with ΔLVESV for QRSd 203 
and Tarea (Figure 2).  204 
QRSarea and focal scar burden between non-ischemic (n = 17) and ischemic patients (n = 205 
16) were additionally compared. QRSarea was lower (p = 0.046) in patients with 206 
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ischemic cardiomyopathy (median: 62, IQR: 27-83) compared to patients with non-207 
ischemic cardiomyopathy (median: 106, IQR: 58-145), while focal scar burden did not 208 
differ between the two groups (all p >0.136) 209 
 210 
ROC analyses for CMR and VCG parameters identifying CRT response  211 
Pre-T1 and ECV were poor predictors for CRT response, while Scar2SD and Gray2SD were 212 
substantially better at predicting CRT response ([AUC: 0.692, p=0.063] and [AUC: 0.759, 213 
p=0.012] respectively). QRSarea, but not QRSd, Tarea or QRSTarea, significantly predicted 214 
CRT response (AUC: 0.737, p = 0.022) (Figure 3, Table 3). 215 
 216 
Association between VCG and myocardial scar 217 
There was no association between pre-T1 or ECV and QRSarea or Tarea (all p>0.142). All 218 
VCG parameters inversely correlated with Scar2SD and Gray2SD.The strongest VCG-CMR 219 
association was found between QRSarea and focal scar parameter Scar2SD (Figure 4). 220 
 221 
Combining VCG and CMR scar parameters 222 
The study population was dichotomized using the cut-off values for Scar2SD, Gray2SD and 223 
QRSarea derived from the ROC analyses in Table 3. The percentage of CRT responders 224 
was significantly higher in patients with low Gray2SD and low Scar2SD versus patients 225 
with high focal scar parameters (Figure 5A). The percentage of CRT response was also 226 
higher in patients with high QRSarea as compared to those with low QRSarea (Figure 5B).  227 
Crosstab analyses between QRSarea and Gray2SD/Scar2SD showed that the percentage CRT 228 
response was highest (92%) in patients with a combination of high QRSarea (>66 mV.ms) 229 
and low Gray2SD (≤5.91% LV mass)/low Scar2SD (≤20.29% LV mass). The four subgroups 230 
in Scar2SD+QRSarea combinations differed significantly from each other (overall: p<0.001; 231 
Figure 5C). For Gray2SD+QRSarea combinations, the subgroup [low Gray2SD+high QRSarea] 232 
was significantly different from the other three subgroups, while the subgroups [low 233 
Gray2SD+low QRSarea] and [high Gray2SD+high QRSarea] were not significantly different.  234 
 235 
Discussion  236 
The present study is the first to investigate the relationship between VCG parameters 237 
and CMR defined scar, and between these parameters and CRT response. The principal 238 
findings of this study are that QRSarea significantly correlated inversely with focal scar, 239 
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suggesting that myocardial scar leads to a smaller QRSarea, Additionally, by combining 240 
QRSarea and CMR focal scar assessment, CRT response prediction improves beyond that 241 
by either VCG or scar parameters alone.  242 
 243 
The role of VCG in clinical context  244 
The VCG technique was first described almost a century ago. VCG measures the 245 
electrical activity of the heart as a vector loop consisting of momentary magnitudes and 246 
directions in 3D space for each time point in the heart cycle. Various VCG systems have 247 
been introduced, from which the Frank VCG system (employing seven recording 248 
electrodes) was the most common VCG system in clinical care in the 1960s together 249 
with the current 12-lead ECG system.(11) After two periods of discontinuation in 250 
clinical practice, interest in the use of VCG regained in the late 1980s, and mathematical 251 
matrices were developed to synthesize the VCG from the 12-lead ECG.(3) Advantages of 252 
VCG parameters over the 12-lead ECG-derived morphology definitions (like LBBB) is 253 
that VCG parameters are objective continuous parameters and therefore more suitable 254 
for statistical analyses. QRSarea and Tarea defined as the 3D integral of the QRS- and T-255 
wave loop respectively, resemble dispersion of depolarization and repolarization, and 256 
are the most common VCG parameters recently investigated in CRT.(2, 4, 12-14)  257 
 258 
The association between VCG and CMR scar  259 
The usefulness of VCG for identification of myocardial scar has been investigated by 260 
Bizarro et al. almost four decades ago.(15) In this small study, automatically generated 261 
VCG parameters from both the QRS- and T-  loop were able to identify 85% of the 262 
patients with autopsy-confirmed scar. Ever since, the majority of studies have focused 263 
on comparing features from the 12-lead ECG with myocardial scar.(16, 17) However, 264 
the use of these ECG criteria in estimating scar extent is complex and particularly 265 
debatable in patients ventricular conduction disturbances.(17)  266 
In the present study, correlation analyses suggested that QRSarea decreased with focal 267 
scar burden (encompassing dense scar core), and to a lesser extent scar border zone; 268 
but VCG parameters were not significantly associated with measures of diffuse fibrosis. 269 
This suggests that scar tissue with higher density affects the VCG 3D loop the most.   270 
A low QRSarea theoretically resembles less dispersion and subsequently a small amount 271 
of unopposed forces during ventricular depolarization. The size of these forces likely 272 
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depends on the uniformity of slow conduction and the amount of viable myocardium. A 273 
lower number of viable myocardial cells, lateralization of connexins, and increased axial 274 
resistivity after myocardial infarction may lead to a decrease of total electrical forces 275 
during the cardiac cycle and therefore an overall decrease of VCG amplitude, and 276 
subsequently low QRSarea and Tarea.(18) 277 
QRSarea is not only affected by the severity of focal myocardial scar, but may also be 278 
affected by the etiology of heart failure alone. Van Deursen et al.(4) reported lower 279 
QRSarea in patients with ischemic cardiomyopathy compared to patients with non-280 
ischemic cardiomyopathy.  281 
 282 
The role of VCG in CRT response prediction 283 
The significant association of a large QRSarea with more LV reverse remodeling after CRT 284 
is in line with earlier studies demonstrating a significant association of QRSarea with CRT 285 
response.(2, 4) QRSarea has been shown to be associated with delayed electrical 286 
activation on the LV lateral wall.(19) QRSarea is thought to represent unopposed 287 
ventricular contraction forces. A larger QRSarea therefore reflects a greater degree of 288 
ventricular electrical dyssynchrony which  is   amenable to CRT.(4, 20)    289 
The strength of QRSarea in predicting CRT response is particularly demonstrated in the 290 
recent multicenter prospective MARC study where numerous clinical, 291 
echocardiographic, blood, and electrocardiographic biomarkers were studied and 292 
related to LV reverse remodeling.(2) From all these biomarkers, only QRSarea and 293 
echocardiographic interventricular mechanical delay and apical rocking remained 294 
significantly associated with LV reverse remodeling in the multivariable model. 295 
Although in their data  Tarea showed a significant association with LV reverse 296 
remodeling in the unadjusted model (p-value <0.001), significance was not preserved in 297 
the multivariate model.(2) Interestingly, Tarea proved to predict CRT response slightly 298 
better than QRSarea in retrospective studies by Engels and Vegh et al.(4, 13) The sum of 299 
the absolute QRST integral (SAI QRST) has also been investigated as a predictor for LV 300 
reverse remodeling. In 234 CRT recipients from the SMART-AV trial by Tereshchenko et 301 
al.(14) found that patients with a high QRSTarea had significantly greater odds of LV 302 
reverse remodeling than those with lower QRSTarea. QRSTarea was also associated with 303 
∆LVESV reduction in our data but was not a significant CRT response predictor in the 304 
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ROC analyses (p = 0.074). Altogether these results indicate that the role for Tarea in CRT 305 
response prediction is not fully understood yet.(4, 13, 14)  306 
 307 
The relevance of myocardial scar regarding CRT response  308 
The association between focal scar burden and poor CRT response has been 309 
investigated in numerous studies. Chalil et al. demonstrated that CRT recipients with a 310 
scar size of <33% showed significantly more favorable clinical response to patients with 311 
≥33% scar. Patients with a posterolateral scar, the common site for LV lead placement, 312 
also had a higher risk of cardiovascular death and HF hospitalization.(9) Leyva et al. 313 
concordantly studied the use of DE-CMR to guide LV lead placement remote from scar 314 
tissue in a large cohort of 559 patients. In their data, patients with DE-CMR confirmed 315 
scar showed the highest risk of cardiovascular death and lowest echocardiographic CRT 316 
response, confirming the importance of pacing remote from scar.(5)  317 
After the introduction of T1 mapping in CMR, a few studies additionally investigated the 318 
potential role of diffuse fibrosis in CRT response.(6, 21) The association between diffuse 319 
fibrosis and focal scar and LV reverse remodeling was studied by Chen et al. 320 
prospectively in CRT candidates with ischemic and non-ischemic etiologies of HF.(6) In 321 
a multivariate model only focal scar burden, but not diffuse fibrosis, was able to predict 322 
LV reverse remodeling significantly. Höke et al investigated the association of diffuse 323 
fibrosis with CRT response prediction specifically in the non-ischemic cohort (21). In 324 
their data both focal scar as well as diffuse fibrosis were associated with LV reverse 325 
remodeling after CRT. These findings indicate that diffuse fibrosis may have a potential 326 
role in CRT response prediction in patients with non-ischemic cardiomyopathy.  327 
 328 
Combining VCG with CMR for a better CRT response prediction 329 
The present study demonstrates that combining parameters reflecting both electrical 330 
and tissue substrate for CRT may be an approach to further improve CRT response 331 
prediction. Almost all (92%) patients with a low extent of focal scar and a large QRSarea 332 
were CRT responders. This finding is important, since myocardial scar burden and 333 
QRSarea are inversely related to each other. Apparently, CRT response prediction is 334 
better when incorporating focal scar metrics in addition to QRSarea compared to using 335 
QRSarea alone. Potential explanations for the negative effect of scar on CRT may be that 336 
1) scar is inherent to non-viable myocytes and therefore reduces the amount of normal 337 
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myocardium that can be resynchronized, 2) pacing in scar may reduce 338 
resynchronization as electrical propagation may be inhibited by slow conducting 339 
(scarred) myocardium .  340 
 341 
Clinical implications 342 
The present study supports the earlier findings that QRSarea may improve the selection 343 
of CRT candidates and extents this idea by demonstrating that further improvement in 344 
selection may be obtained by combining scar characterization using CMR and VCG 345 
analysis. The refined positive predictive value using such combined VCG-CMR focal scar 346 
index is highly encouraging, in particular in the ischemic cardiomyopathy cohort, in 347 
whom the CRT response is commonly low.(22)  348 
 349 
Limitations 350 
This study incorporated a relative small number of patients from a single center with 351 
the inherent limitation of such study design. Nevertheless, the consecutive patient’s 352 
cohort reflects a broad real-world experience.  353 
QRSarea in the present study is slightly lower compared to previous publications,(5, 6) 354 
which may be explained by the lower QRS duration and fewer LBBB morphologies in 355 
our study population compared to the populations from Maass et al.(6) and Engels et 356 
al.(4) The optimal thresholding values for the scar VCG parameters should be taken in 357 
the context of the study and a larger population study is needed to validate these 358 
optimal thresholding values and different cut-offs may be required in ischemic and non-359 
ischemic cardiomyopathy. 360 
 361 
Conclusion  362 
Focal scar CMR parameters and QRSarea are independent predictors for CRT response 363 
and are inversely associated with each other. The highest percentage of CRT response 364 
was observed in patients with low focal scar CMR values and high QRSarea, indicating 365 
that combined CMR-VCG parameters may improve prediction to CRT response.  366 
 367 
 368 
 369 
  370 
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Table 1  449 
Patient characteristics 450 
Demographics  QRSarea p-value 
 Total patient no.   33  
 Age (years) 65±12 0.569 
 Male 27 (82%) 0.479 
 Ischemic cardiomyopathy  16 (49%) 0.045* 
 NYHA (II/III/IV)  1 (3%) / 31 (94%) / 1 (3%) 0.270 
 LVEF (%)  24±8 0.681 
 ECG QRS duration (ms) 150±22 0.016* 
 ECG LBBB morphology 12 (36%) <0.001* 
 CRT response (reduction ∆LVESV ≥15%)  19 (58%) 0.021* 
 451 
Values are displayed as mean and standard deviation or n (%). The association between patient 452 
characteristics and QRSarea was investigated using Spearman correlation analyses for 453 
continuous variables and Mann Whitney u or Kruskal Wallis tests for dichotomous variables.  454 
BMI=body-mass-index, EDV=end-diastolic volume, ESV=end-systolic volume, LBBB=left bundle 455 
branch block, LV=left ventricular, LVEF=LV ejection fraction, NYHA=New York Heart 456 
Association. 457 
 458 
 459 
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Table 2  461 
Parameter value differences between responders and non-responders to CRT 462 
  CRT non-responders 
(n=14) 
CRT responders 
(n=19) 
p-value 
T1 mapping (diffuse fibrosis)   
 Pre-T1 (ms) 1063 (984-1098) 1065 (1002-1105) 0.706 
 ECV (%) 0.33 (0.29-0.37) 0.29 (0.24-0.35) 0.152 
     
DE-CMR (focal scar)   
 Gray2SD (%) 7.27 (5.48-10.37) 3.83 (1.69-6.10) 0.011* 
 Scar2SD (%) 26.16 (18.69-28.84) 13.29 (4.55-26.83) 0.065 
     
 VCG parameters    
 QRSd (ms) 145 (125-161) 151 (144-168) 0.199 
 QRSarea (mV.ms) 59 (33-78) 106 (62-163) 0.021* 
 Tarea (mV.ms) 41 (32-63) 42 (25-90) 0.577 
 QRSTarea (mV.ms) 33 (29-68) 57 (34-85) 0.077 
 463 
Responders are defined as reduction of LVESV ≥15%. P-values are based Mann Whitney 464 
u-tests. Continuous variables are displayed as median and interquartile ranges. 465 
*indicates significance (p-value ≤0.05).  466 
 467 
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Table 3 469 
ROC analyses predicting CRT response (∆LVESV ≥15%) for CMR and VCG parameters  470 
  AUC CI p-value Threshold Sensitivity Specificity 
T1 mapping (diffuse fibrosis)      
 Pre-T1 (ms) 0.461 0.258-0.663 0.702 <1063 47% 50% 
 ECV (%) 0.650 0.455-0.846 0.145 <0.32 68% 72% 
        
DE-CMR (focal scar)     
 Gray2SD (%) 0.759 0.586-0.933 0.012* <5.91 74% 71% 
 Scar2SD (%) 0.692 0.503-0.881 0.063 <20.29 68% 72% 
        
VCG        
 QRSd (ms) 0.635 0.438-0.832 0.190 >148 63% 57% 
 QRSarea (mV.ms) 0.737 0.564-0.910 0.022* >66 74% 71% 
 Tarea (mV.ms) 0.560 0.358-0.762 0.560 >39 63% 50% 
 QRSTarea (mV.ms) 0.684 0.493-0.875 0.074 >36 74% 64% 
*indicates significance (p-value ≤0.05).  471 
 472 
 473 
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Figure 1 475 
Graphical representation of CMR and VCG assessment approach.  476 
  477 
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Figure 2 478 
Scatter plots of VCG and CMR scar parameters vs. ∆LVESV (%). Correlation coefficients 479 
are based on Spearman correlation analyses.  480 
 481 
 482 
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Figure 3 484 
ROC analyses predicting CRT response (∆LVESV ≥15%) for CMR focal scar parameters 485 
(upper left) and VCG parameters (upper right). Accompanying details of the ROC 486 
analyses are provided in Table 3.   487 
 488 
 489 
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Figure 4 491 
Scatter plots of CMR scar parameters vs. VCG parameters. Correlation coefficients are 492 
based on Spearman correlation analyses. All focal scar CMR parameters correlated 493 
inversely with the VCG parameter. 494 
 495 
 496 
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Figure 5 502 
2D bar graphs showing CRT response percentage per focal scar CMR (A) and VCG (B) 503 
parameter when dividing the study population using the cut-off value as determined by 504 
ROC analyses in Table 3. P-values in A and B are based on Chi-squared tests.   505 
3D bar graphs demonstrating CRT response percentage when combining QRSarea with 506 
focal scar CMR parameters (C). P-values in each graph are based on Fisher’s exact tests.  507 
 508 
 509 
